Literature DB >> 3457609

Remission-induction of acute lymphoblastic transformation of chronic myeloid leukaemia, followed by long-term maintenance therapy.

T de Witte, B de Pauw, C Haanen.   

Abstract

Acute lymphoblastic transformation of chronic myeloid leukaemia (LT-CML) of 7 consecutive patients was treated according to a remission-induction and maintenance therapy used for de novo acute lymphoblastic leukaemia (ALL). All 7 patients achieved a second chronic phase with a median remission duration of 15 months. Two patients showed an isolated central nervous system (CNS) relapse. This did not occur in the 4 patients, who received prophylactic therapy with intrathecal methotrexate. The second transformation was nonlymphoblastic in nature in 4 out of the 5 patients. A treatment protocol similar to that of a bad risk ALL, including long-term maintenance therapy and CNS-prophylaxis is indicated in lymphoblastic transformation of CML.

Entities:  

Mesh:

Year:  1986        PMID: 3457609     DOI: 10.1007/BF00321082

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  12 in total

1.  Repetitive cycles of cytoreductive therapy followed by stem cell autografting for nonlymphoblastic transformation of chronic granulocytic leukaemia.

Authors:  T de Witte; R Raymakers; B de Pauw; C Haanen
Journal:  Scand J Haematol       Date:  1985-11

Review 2.  Recent advances in the biology and treatment of acute lymphoblastic leukemia in adults.

Authors:  A D Jacobs; R P Gale
Journal:  N Engl J Med       Date:  1984-11-08       Impact factor: 91.245

3.  Monoclonal antibody (WT 1) directed against a T cell surface glycoprotein: characteristics and immunosuppressive activity.

Authors:  W J Tax; N Tidman; G Janossy; L Trejdosiewicz; R Willems; J Leeuwenberg; T J De Witte; P J Capel; R A Koene
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

Review 4.  Chronic myelogenous leukemia--new concepts (first of two parts).

Authors:  H P Koeffler; D W Golde
Journal:  N Engl J Med       Date:  1981-05-14       Impact factor: 91.245

5.  Differentiation patterns in the blastic phase of chronic myeloid leukemia.

Authors:  J D Griffin; R F Todd; J Ritz; L M Nadler; G P Canellos; D Rosenthal; M Gallivan; R P Beveridge; H Weinstein; D Karp; S F Schlossman
Journal:  Blood       Date:  1983-01       Impact factor: 22.113

6.  Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia: a co-operative study.

Authors:  S M Marks; D Baltimore; R McCaffrey
Journal:  N Engl J Med       Date:  1978-04-13       Impact factor: 91.245

7.  Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy.

Authors:  G P Canellos; V T DeVita; J Whang-Peng; B A Chabner; P S Schein; R C Young
Journal:  Blood       Date:  1976-06       Impact factor: 22.113

8.  Treatment of acute lymphoblastic leukemia in adolescents and a-dults: A retrospective study of 41 patients (1970-1973).

Authors:  R Willemze; H Hillen; C A Hartgrink-Groeneveld; C Haanen
Journal:  Blood       Date:  1975-12       Impact factor: 22.113

9.  Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage.

Authors:  P J Fialkow; R J Jacobson; T Papayannopoulou
Journal:  Am J Med       Date:  1977-07       Impact factor: 4.965

10.  Nonrandom chromosomal abnormalities in hematologic disorders of man.

Authors:  J D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.